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Screening for illicit drugs in pooled human
urine and urinated soil samples and studies on
the stability of urinary excretion products of
cocaine, MDMA, and MDEA in wastewater by
hyphenated mass spectrometry techniques
Marie Mardal,a Juliet Kinyua,b Pedram Ramin,c Bram Miserez,d
Alexander L. N. van Nuijs,b Adrian Covacib and Markus R. Meyera,e*
Monitoring population drug use through wastewater-based epidemiology (WBE) is a useful method to quantitatively follow
trends and estimate total drug consumption in communities. Concentrations of drug biomarkers might be low in wastewater
due to dilution; and therefore analysis of pooled urine (PU) is useful to detect consumed drugs and identify targets of illicit drugs
use. The aims of the study were (1) to screen PU and urinated soil (US) samples collected at festivals for illicit drug excretion prod-
ucts using hyphenated techniques; (2) to develop and validate a hydrophilic interaction liquid chromatography –mass spectrom-
etry / mass spectrometry (HILIC-MS/MS) method of quantifying urinary targets of identified drugs in wastewater; and (3) to
conduct a 24h stability study, using PU and US to better reflect the chemical environment for targets in wastewater. Cocaine
(COC) and ecstasy-like compounds were the most frequently detected illicit drugs; an analytical method was developed to
quantify their excretion products. Hydroxymethoxymethamphetamine (HMMA), 3,4-methylenedioxymethamphetamine (MDMA),
3,4-methylenedioxyamphetamine (MDA), HMMA sulfate (HMMA-S), benzoylecgonine (BE), and cocaethylene (CE) had 85–102% of
initial concentration after 8h of incubation, whereas COC and ecgoninemethyl ester (EME) had 74 and 67% after 8h, respectively.
HMMA showed a net increase during 24h of incubation (107%±27, n=8), possibly due to the cleavage of HMMA conjugates, and
biotransformation of MDMA. The results suggest HMMA as analytical target for MDMA consumption inWBE, due to its stability in
wastewater and its excretion as the main phase I metabolite of MDMA. Copyright © 2016 John Wiley & Sons, Ltd.
Keywords: pooled urine analysis; illicit drugs; phase II metabolites; stability; wastewater-based epidemiology
Introduction
Analysis of wastewater for illicit drugs is a complementary ap-
proach to surveys for obtaining data on drug consumption
trends in a community, since wastewater can be considered as
a large, strongly diluted, pooled urine (PU) sample.[1–3]
Wastewater-based epidemiology (WBE) estimates drug con-
sumption at the community level by quantifying excretion prod-
ucts (drug and/or its metabolites) in wastewater and back
calculating concentration of these targets to actual drug con-
sumption. An important prerequisite for these back calculations
is the knowledge about the best biomarkers to reflect human
consumption and their stability in the sewer.[4,5]
As illicit drugs can be extensively metabolized in humans, knowl-
edge of their metabolism and stability of metabolites is of great
interest.[6] Obtaining authentic urine samples with excretion prod-
ucts of illicit drugs can be challenging for ethical and legislative rea-
sons. Pooled urine analysis (PUA) can overcome some of these
issues and reveal the nature and type of drugs consumed by an in-
vestigated population.[7–10] Furthermore, PUA offers realistic excre-
tion patterns of illicit drugs and is easily accessible. Apart from PU,
another way to collect urine is through urinated soil (US) samples.
At events where people urinate in places other than lavatories
and urinals, pools of urine and urinary metabolites can accumulate
on the soil.
Stability data in wastewater are mainly available for drugs, but
also for some metabolites.[4,5,11–13] Gomes et al. tested the stability
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of estrogen phase II metabolites in wastewater and concluded that
sulfates should have a high stability (above 80%) after 8 h and
glucuronides being below detection limit after 8 h of incubation.[14]
So far, only one study has investigated the stability of phase II
metabolites of illicit drugs in wastewater. Glucuronides of 3,4-
methylenedioxypyrovalerone (MDPV) degraded in wastewater af-
ter 24h, whereas sulfates mostly remain intact.[4] Currently used
targets for cocaine (COC) and 3,4-methylenedioxymetham-
phetamine (MDMA) consumption in WBE are benzoylecgonine
(BE) and MDMA itself, respectively.[15] However, MDMA is known
to be highly metabolized before being excreted into urine and
hydroxymethoxymethamphetamine (HMMA) sulfates were found
to be themost abundant products.[16] UsingMDMA itself as a target
in WBE will not allow distinction between drug consumption and
discharge.
Therefore, the aims of the present study were to collect PU and
US samples from festivals and to screen these samples for excretion
products of illicit drugs by mass spectrometry. Furthermore, an
analytical method to quantify COC, MDMA 3,4-methyle-
nedioxyethyleamphetamine (MDEA), and their main metabolites
(Figure 1) in wastewater for stability studies was validated. Finally,
PU and US were incubated in wastewater and the stability of the in-
vestigated compounds, including their conjugates, was assessed
over time.
Experimental
Chemicals and reagents
COC, COC-d3, cocaethylene (CE), CE-d3, BE, BE-d3, MDEA-d5,
and HMMA were obtained by LGC standards, ecgonine methyl
ester (EME) and EME-d3 were obtained from Cerilliant
(Round Rock, TX, USA). HMMA-d3, MDMA, MDMA-d5, 3,4-
methylenedioxymethamphetamine (MDA), and MDA-d5 were
obtained from Sigma-Aldrich (St Louis, MO, USA). HMMA sulfate
(HMMA-S) was produced as described previously.[17]
Hydroxymethoxyethylamphetamine (HMEA) was produced as
described previously.[18] MDEA was obtained from seized mate-
rials. Dilutions and storage of COC and its metabolites were
done in acetonitrile, for MDMA and metabolites in methanol.
Isolute C18 (500mg, 3mL) and HCX cartridges (130mg, 3mL)
were obtained from Biotage (Uppsala, Sweden). Mixture (100
Figure 1. Chemical structures of the investigated excretion products. Arrows indicate metabolic pathways.
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000 U/mL) of glucuronidase (EC No. 3.2.1.31) and arylsulfatase
(EC No. 3.1.6.1) from H. Pomatia and analytical grade ammo-
nium acetate from Merck (Darmstadt, Germany). All other
chemicals and reagents (analytical grade), and centrifugal filters
were from VWR (Darmstadt, Germany). The P-Tree Urinal was
from Aandeboom (Utrecht, the Netherlands).
Collection of pooled urine samples and urinated soil samples
All samples were collected at two European music festivals in 2014.
PU samples were collected by two different methods:
A. Extracted from tulip urinals (individually collected PU sam-
ples, n = 11) using a plastic hose and plastic syringe, collected
from three independent urinals at different time points over
three days.
B. Collected from urinals (Pee tree urinals, n = 10) mounted on a
wall, connected to a 30 L container located in a protected
environment.
All PU samples were spiked on site with HMMA-d3 to a final con-
centration of 100ng/mL and stored in polystyrene containers and
immediately put on ice until freezing (max 12h).
US was collected from areas (fences, bushes, etc.) where pools of
urine were visible on the surface. The characteristics (liquid content,
colour, type of soil) differed from urine with small amounts of sand
to humus with high organic content.
Sample preparation and screening analysis of urine samples
and urinated soil samples
An overview of sample preparation of PU and US is presented in
Figure 2. Sample preparation for PU was according to previously
published standard urine sample protocols, to identify excretion
products (parent drug and metabolites) of illicit and therapeutic
drugs.[19] Briefly, Phase I metabolites were identified after enzy-
matic cleavage of conjugates in 1mL PU added internal standard
(1μg/mL trimipramin-d3); basic and neutral/acidic phase I metabo-
lites were then separated by applying the cleaved PU onto HCX
cartridges and dividing each fraction into two. One fraction was
acetylated and injected onto gas chromatography-mass spectrom-
etry (GC-MS) using a Hewlett Packard (HP, Waldbronn, Germany)
5890 Series II gas chromatograph system. The other part was ana-
lyzed by liquid chromatography-high resolution-tandem mass
spectrometry (LC-HR-MS/MS) using a Thermo Fisher Q Exactive
and LC-ion trap mass spectrometry (LC-MSn) using a Thermo Fisher
LXQ both coupled to Accela LC systems. Phase II metabolites were
identified after extracting 1mL PU added internal standard (1μg/
mL trimipramin-d3) on C18 cartridges and after precipitation of
100μL PU with 500μL acetonitrile, then analyzed using LC-HR-
MS/MS and LC-MSn mentioned above (Figure 2).[20,21] Acquired
LC-HR-MS/MS data were analyzed for common new psychoactive
substances (NPS) and metabolites, by extracting ion chromato-
grams from full scan, as well as mining MS spectra in data-
dependent mode.[20]
Sample preparation for US was as follows: 0.5 g of US was mixed
with 0.5mL acetonitrile with internal standard (100ng/mL HMMA-
d3). This mixture was thoroughly vortexed and centrifuged for
5min at 18,407g and 10μL were injected onto the LC-HR-MS/MS
and LC-MSn systems as used for the PU samples, with instrument set-
tings as previously reported for standard human urine samples.[19–21]
Collection of wastewater samples
Wastewater was collected for the stability assessment of urinary tar-
gets on a dry day as a 24h time-proportional composite sample
from a wastewater treatment plant in Wulpen, Belgium.
Instrumentation for wastewater incubations
The LC system consisted of an Agilent 1200 series High Pressure LC
fitted with a degasser, a binary high-pressure gradient pump, a
heated column compartment and an autosampler module without
cooling. Chromatographic separation was achieved using a
Phenomenex LUNA HILIC 200Å (150 x 3mm, 5μm) column, with
a mobile phase composed of A) 5mM ammonium acetate in ultra-
pure water and B) acetonitrile, at a flow rate of 0.4mL/min. The gra-
dient was as follows: 0–0.5min 95% B, 0.5–6.5: 60% B, 6.5–9min:
52% B, 9–9.5min: 95% B. The total runtime, including column
Figure 2. Overview of instrumentation and sample preparation methods for screening pooled urine and urinated soil samples for illicit drugs and
therapeutic drugs.
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equilibration, was 15.5min. All compounds were eluted within
8min. The injection volume was set to 2μL. The LC system was
coupled to an Agilent 6410 triple quadrupole mass spectrometer
with an electrospray interface (ESI) for detection and quantification
of the compounds. Source parameters were as follows: gas temper-
ature of 350 °C, gas flow 12 L/min, nebulizer 40 psi, capillary voltage
+4000V and delta EMV 450, time frame was set to 0.15min. The
mass spectrometer compound dependent parameters were opti-
mized for each compound individually (Table 1) by direct injection
(without analytical column) of standards using MassHunter Opti-
mizer (v. B 03.01) Source parameters (gas temperature, gas flow,
nebulizer pressure, and capillary voltage) were optimized to acquire
an intense protonated molecular species [M+H]+ for each com-
pound. Mass spectrometer compound dependent parameters,
fragmentor voltage, and collision energy were optimized to acquire
two multiple reaction monitoring (MRM) transitions (qualifier and
quantifier) for each compound, including internal standards. The
most abundant transition was chosen as quantifier (Q) and the sec-
ond most abundant transition as qualifier (q). The Q/q ratio was
monitored for variation (RSD 20%) to provide an additional identifi-
cation criterion besides the retention time. For LC optimization, a
mix of standards with all compounds was injected on three differ-
ent HILIC columns for evaluation of separation power. In addition,
different injection volumes (1, 2, 3, and 5μL) were tested, and opti-
mized based on effect on peak shape.
Method validation for analysis of wastewater incubations
Method validation was based on the EMA guidelines on
bioanalytical method validation with some exceptions.[22] Precision,
accuracy, linearity, selectivity, calibration range, lower limit of quan-
tification (LLOQ) and sensitivity were tested. Multi-component cali-
bration curves were established in wastewater with a minimum of
six calibration points, by spiking stock solution into previously col-
lected grab samples wastewater, then mixing 50μL spiked waste-
water with 50μL internal standard in acetonitrile, filtering samples
through 0.45μm nylon membrane filter units and centrifuging
them for 5min at 18 000 g. Signals from each analyte were
corrected for their corresponding deuterated internal standard
(IS), with the exceptions of HMMA and HMMA-S, where MDMA-d5
was used as internal standard. IS was prepared by diluting stock so-
lutions in acetonitrile to a final concentration in prepared sample of
84ng/mL for COC-d3, CE-d3, and MDMA-d5, 40 ng/mL for EME-d3
and BE-d3, and 140ng/mL for MDA-d5 and MDEA-d5.
A blank sample (wastewater sample with acetonitrile) and a zero
sample (wastewater sample with IS) were run together with the cal-
ibration curves. The medium quality control (QCmed) was prepared
for the method validation, and additionally two quality controls,
one low (QClow) and one high (QChigh) were added for the analytical
runs. QCs were prepared in the same way as calibration points and
used to calculate accuracy and precision. Calibration curves for
quantification were constructed in Agilent MassHunter Quantita-
tive Browser by plotting peak areas of the analytes divided by the
corresponding internal standard, against the spiked concentration
and weighted by 1/x. Carryover was tested by injecting the blank
after the highest calibrator and repeated three times.
Intra- and inter-day accuracy and precision were based on calcu-
lating concentrations of quality control samples from established
calibration curves, using QCmed (n= 6) for intra-day and all three
QCs (n= 6-13) for inter-day accuracy and precision. The results were
assessed with an acceptance criterion within 85–115% (mean) ac-
curacy and< 15% precision, as confidence value (CV). LLOQ was
based on visual inspection, and complied with EMA guidelines on
±20 % back-calculated concentrations.
Stability assessment of urinary targets in wastewater
The workflow for the multi-step preparation of the incubations is
presented in Figure 3. Screening analysis provided estimations on
which PU and US samples had high and low concentrations of
COC, MDMA, and MDEA excretion products, respectively. These es-
timations were used to design wastewater incubations with high,
low, or medium concentrations of COC, MDMA, and MDEA excre-
tion products. A blank incubation was run to correct for possible
Table 1. Optimized MRM transitions and retention times for selected compounds and the deuterated internal standards.
Quantifier Qualifier
Compound Name Retention
time, min
Precursor
ion, m/z
Fragmentor
voltage, V
Collision
energy, V
Product
ion, m/z
Product
ion, m/z
Benzoylecgonine 5.3 290.1 124 14 168.1 105.1
Benzoylecgonine-d3 5.3 293.2 122 13 171.1 105.0
Cocaethylene 5.8 318.2 134 14 196.1 82.1
Cocaethylene-d3 5.9 321.2 132 16 199.1 85.1
Cocaine 5.4 304.2 124 14 182.1 82.1
Cocaine-d3 5.6 307.1 124 14 185.1 85.1
Ecgonine Methyl Ester 7.5 200.2 124 14 182.1 82.1
Ecgonine Methyl Ester-d3 7.6 203.2 118 14 185.1 85.1
HMEA 7.4 210.1 89 4 165.1 137.1
HMMA-S 4.1 276.0 105 12 165.1 137.1
HMMA 7.7 196.1 88 8 165.1 137.1
MDA 7.4 180.2 80 4 163.1 105.1
MDA-d5 7.5 185.2 80 4 168.1 110.1
MDEA 7.1 208.2 88 9 163.0 105.1
MDEA-d5 7.1 213.1 92 8 163.1 105.1
MDMA 7.3 194.1 92 9 163.0 105.1
MDMA-d5 7.3 199.1 92 21 163.1 107.1
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back-ground excretion products present in wastewater. Only PU
and US with COC, MDMA, and/or MDEA excretion products were
used for stability assessment of urinary targets in wastewater. To
investigate stability of phase I metabolites and parent drug with
minimal interference from phase II metabolites, three wastewater
incubations were prepared with conjugate cleaved PU (Figure 3),
from PU samples tested positive for COC and MDMA excretion
products in the screening analysis. Three PU samples were enzy-
matically cleaved by adjusting them to pH to 5.2 ± 0.1 with 0.1M
HCl and 0.1M NaOH, then adding 50μL glucuronidase/
arylsulfatase, and incubating the mix for 30min at 70 °C in a GC
oven.
Step 1: Concentration of analytes
All samples were concentrated by precipitation with methanol and
evaporation to dryness. Five mL PU, US, cleaved urine, or blank
urine were mixed with ice cold methanol (50:50 v/v %) and centri-
fuged for 10min at 2000g. The supernatants were evaporated to
dryness at 40 °C under a gentle stream of nitrogen.
Step 2: Dissolving in wastewater
The concentrated PU, US, cleaved urine, or blank urine was diluted
in wastewater to fit the calibrated range. A total volume of 4mL of
each incubation was transferred to 50mL falcon tubes.
Step 3: Incubations
All samples were incubated at 23 °C in a temperate water bath for
24 h. Sampling of each incubation was made after 0, 0.5, 1, 2, 3, 5,
8, 12, and 24h.
One of the incubations (IncA) was divided into three separate
containers to assess biological variance (IncA, BioVarX, BioVarZ),
i.e., the variance introduced by different transformation from the bi-
ological communities in wastewater. Incubation pH was monitored
with indicator paper.
Sample preparation of wastewater incubations
An aliquot of 50μL from the wastewater incubations was mixed
with 50μL internal standard in acetonitrile and samples were
filtered through 0.45μmnylonmembrane filter units that were cen-
trifuged for 5min at 18 000g.
Evaluation of analytical data for stability studies
Variance introduced post-injection (analytical variance), from the
sample preparation (sample preparation variance) and from vari-
ance introduced by different transformation from the biological
communities in wastewater (biological variances) were assessed
for MDMA and COC excretion products in real samples. Biological
variance was assessed after 3, 12, and 24h. Analytical and sample
preparation variances were tested using IncC and IncG from a sin-
gle time point, respectively. Both samples were prepared five times
(sample preparation variance) and one of these was injected five
times (analytical variance). F-tests were calculated using Microsoft
Excel 2007 add-in program, Analysis ToolPak F-test.
Compound stability compared to initial concentration was classi-
fied using slightly modified definitions presented byMcCall et al.[23]
A compound had a high stability when more than 80 % of the orig-
inal concentration remained after defined time period, medium sta-
bility when 40-80 % remained, and a low stability when less than
40% remained. Stability was assessed after 8 and 24h.
Results and discussion
Screening of pooled urine samples and urinated soil samples
Two different analytical systems (GC and LC) have been used to
cover a wide range of analytes. The methods used are expected
to be comprehensive to each other and were therefore used to
screen for therapeutic drugs as well as for drugs of abuse originat-
ing from different drug classes. COC and MDMA were the most fre-
quently detected illicit drugs in the investigated PU andUS samples
(Table 2). Other identified illicit drugs were MDEA, MDA, metham-
phetamine, amphetamine, ketamine, and sildenafil. All compounds
except amphetamine were also identified by metabolites. It should
be noted, that the latter two are also therapeutic drugs, but have
potential for non-prescription abuse. MDA is the main excretion
product after MDA use, but is also an excretion product of MDMA
and MDEA.[18,24,25] Signal intensities of MDA in the PU and US
Figure 3. Overview of incubation workflow, which samples are used to assess biological, analytic and sample preparation variance, and nomenclature for
samples. Biosample: PU, US, cleaved PU, or blank urine
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samples were lower than MDMA and MDEA signal intensities, it is
thus assumed to be present as a metabolite of the latter two. The
US samples were found to be a useful addition to the PU samples.
No standard urine screening approaches for illicit drug excretion
products on US were found in the literature. Further studies should
investigate additional sample preparation methods, including con-
jugate cleavage.[26] Ketamine and sildenafil metabolites were only
detected in the US samples. Ketamine might also originate from
other sources than human consumption, such as excretion of veter-
inarian medicine. However, ketamine is mainly abused by people
and used only for veterinarian purposes of large animals. Frequen-
cies of detected illicit drugs are summarized in Table 2. This high
prevalence of COC and MDMA was also seen in PU samples col-
lected from the center of London by Archer et al.[10] However, no
NPS could be detected in our study. This might be explained most
likely by absence of consumption or levels below limit of detection.
In the future, more sensitive and targeted screening strategies may
overcome such limitations in part.[27] Based on the findings from
the screening, MDMA, COC, and MDEA were chosen as substances
to test stability of main urinary excretion products in wastewater.
Analytical method for wastewater incubations
As expected, based on previous studies,[28] HILIC separation of the
compounds of interest was sufficient and robust. HILIC was chosen
as it should be suitable for polar analytes, such as metabolites, and
should increase separation power compared to reverse phase col-
umns for these types of compounds due to the different solid
phases. For the current method, performance was optimized for
method application to stability studies with high concentrations
and simple sample preparation. The range for MDMA and BE were
designed higher than other analytes (Table 3), as the PU and US
screening showed that these two compounds were present in high
concentrations in the PU andUS samples. A reconstructed ion chro-
matogram of quantifier transitions of QCmed for MDMA and BE and
QChigh for the remaining analytes is presented in Figure 4. The peak
of HMMA-S was tailing but precision and accuracy were within± 7
% and 95–107%, respectively. Selectivity, linearity, LLOQ, precision,
accuracy, and carry-over were assessed for the method validation.
All tested parameters were within the ranges defined by the EMA.
A summary of the validation data can be found in Table 3.
The LLOQ of the compounds ranged from 2.7 to 20.6 ng/mL and
the upper limit of quantification from 340.2 to 2574.6 ng/mL with a
minimum of six calibration points. All calibration curves had a
squared correlation coefficient higher than 0.99 using 1/xweighing.
MDMA-d5 was used as internal standard for HMMA and HMMA-S.
The back-calculated concentration of all calibration points were
within± 15 % and±20 % for the LLOQ.
Precision and accuracy were tested inter- and intra-day using
QCmed. Additionally, two QC levels were used in the analytical runs
as autosampler stability was not assessed. Accuracy ranged from 93
to 106 % and precision (as CV at confidence level 0.05) from 1% to
10%.
Matrix effects were not investigated as all incubations, QChigh,
and QClow were made from the same batch of wastewater. Recov-
ery was not tested as it is no longer recommended in the latest
EMA guidelines. Sample preparation consisted of dilution and all
QCs were within limits for accuracy and precision.[22] Neither inves-
tigated excretion products nor interfering compounds could be de-
tected in any blank samples.
Stability of urinary metabolites in wastewater
The validated method was used to investigate the stability of the
excretion products from the PU and US samples spiked in wastewa-
ter. Incubations were designed to give a large initial variance in ab-
solute concentration of COC and MDMA excretion products, based
Table 3. Method validation data: Linear range in ng/mL, number of calibration points for the calibration curve (R2> 0.99 for all calibration curves), ac-
curacy in %, precision in confidence value at α = 0.05, inter-day at 1 concentration level, intra-day at 3 concentration levels.
Linear
range, ng/
mL
Calibration
points
Accuracy, % Precision, %
Inter-day Intra-day Inter-day Intra-day
QCmed QClow QCmed QChigh QCmed QClow QCmed QChigh
n = 6 n = 6 n = 13 n = 6 n = 6 n = 6 n= 13 n = 6
Benzoylecgonine 10.3-2574.6 9 102 94 95 97 1 4 4 3
Cocaethylene 2.7-340.2 8 95 97 96 98 3 2 3 3
Cocaine 5.4-340.2 7 93 100 99 101 2 3 3 3
Ecgonine Methyl Ester 8.2-340.2 6 98 100 100 100 5 9 5 3
HMEA 5.4-340.2 7 103 95 96 96 2 8 4 5
HMMA-S 9.6-340.2 7 95 106 101 107 4 7 4 6
HMMA 2.7-340.2 8 100 94 94 99 3 6 6 5
MDA 8.2-340.2 6 97 99 100 100 2 5 3 2
MDEA 5.4-340.2 7 97 99 97 98 4 5 4 3
MDMA 20.6-2574.6 8 96 99 98 98 3 10 4 10
Table 2. Frequency of detected illicit drugs by GC-MS and LC-(HR)-MSn.
M: metabolites.
Tulip Urinals PeeTree Urinals Urinated Soil
Samples
n = 11 n = 10 n = 12
Cocaine +M 10 6 8
MDMA+M 9 1 8
Ketamine +M 1
Sildenafil +M 1
Amphetamine 3 1 1
MDEA+M 2
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on concentration estimates from screening of PU and US. Concen-
trations of MDEA and HMEA were lower than the calibrated range
for all incubations.
Sorption of COC, BE, andMDMA to solid particulate matter is less
than 5%.[29] Sorption was thus not investigated in the present
study, as the more hydrophilic excretion products are expected to
adsorb in the same order of magnitude or lower.
A variance analysis of three isolated steps was performed. Biolog-
ical, sample preparation, and analytical variances from the study are
summarized in Table 4. Generally, sample preparation and analyti-
cal variance were highest for the two analytes not having deuter-
ated internal standards, i.e., HMMA-S and HMMA.
The confidence values of the stability after 24 h were higher than
after 8 h for all investigated compounds. The most pronounced
confidence values were from the MDMA metabolites. This variance
is likely from the effect of having different absolute and relative
levels of excretion products in the incubations.
Stability data after 8 and 24h are shown in Table 4 and calculated
as the percentage remaining relative to the concentration at t0. Var-
iance is given as confidence value at confidence level 0.05, when
n> 3. Figure 5 shows stability curves over 24 h for the investigated
metabolites as average of start concentration in percentage. After
8 h of incubation, COC and EME showed a medium stability,
whereas BE and CE had a high stability. After 24 h COC and EME
only had one sample in the calibrated range, respectively; BE and
CE had a medium stability after 24 h.
Previous stability studies found spiked BE to be stable over 24 h,
and spiked EME and COC over 8 h.[5,11] Another study found spiked
COC to be stable for 24 h.[12] Spiked CE was found to be stable for
24h,[12] which is in contrast to the findings of the current study. Dif-
ferent experimental conditions of the stability studiesmight explain
such findings. However, overall findings in the present study were
in line with previous findings for investigated COC excretion
products.[5,11,12]
Spiked MDMA has a high stability in wastewater[5,11,12]; this was
also observed in the present study using urine. Urinary MDA has a
marked increase in variation and it should be noted MDA was only
within the calibrated range in four of the eight incubations. MDA is
one of the compounds where the developed method performs
best, based on low variances and high precision and accuracy from
the method validation. An F-test comparing normalized biological
variance (n=3) for MDA after 24h with sample preparation vari-
ance (n= 5) shows that the biological and sample preparation var-
iance are unequal (α=0.05, δMDA,BioVar t24h ≠δMDA,SPVar, F = 17.1,
p = 0.006). An F-test comparing the normalized variance from the
incubations (n=4) for MDA after 24h to the biological variance
(n=3) after 24 h shows the incubation variance to be unequal to
the biological variance (α=0.05, δMDA,IncVar, 24h≠ δMDA,BioVar t24h,
Figure 4. Reconstructed m/z chromatograms for the quantifier transitions of BE and MDMA from medium level quality control sample, the rest from high
level quality control sample. The line at 6.6min indicates change in segments.
Table 4. Incubation data: Incubation range in ng/mL. Stability in average of n samples and at the given time point expressed in a percentage of the
original concentration remaining, confidence interval at α = 0.05. Variance data as standard deviation on normalized data (μ = 1). Biological Variance from
IncA, Sample preparation variance and analytical variance from IncC for MDMA excretion products, and IncG for COC excretion products. NA = not
available
Incubation Range Stability Variance
8 h 24 h Biological variance Sample
prep variance
Analytical
variance
Min Max Average, % CV n Average, % CV n Variance 3 h
(n = 3)
12 h
(n = 3)
24 h
(n = 3)
(n = 5) (n = 5)
HMMA-S <LLOQ 177.8 99 14 6 84 17 6 0.259 0.070 0.029 0.029 0.100 0.084
BE 10.2 730.7 88 5 8 78 8 8 0.142 NA NA 0.014 0.066 0.020
COC <LLOQ 27.5 74 NA 2 19 NA 1 NA NA NA NA 0.026 0.029
CE <LLOQ 57.0 88 3 4 56 12 4 0.083 NA NA NA 0.048 0.076
EME <LLOQ 18.7 67 12 3 46 NA 1 NA NA NA NA 0.022 0.024
HMMA <LLOQ 102.3 102 17 7 107 27 7 0.339 0.027 0.025 0.123 0.061 0.091
MDA <LLOQ 35.2 85 10 4 103 46 4 0.454 0.084 0.035 0.062 0.007 0.032
MDMA <LLOQ 433.5 96 2 7 85 4 7 0.075 0.067 0.024 0.029 0.027 0.012
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F=168.9, p = 0.006). The increased variation could be caused by dif-
ferent biotransformation pathways, such as N-demethylation of
MDMA and O-demethylation to 3,4-dihydroxyamphetamine, as it
was observed for MDPV.[4] Previous studies have found spiked
MDA to be stable in wastewater.[12] Further studies should be en-
couraged for MDA to allow a better understanding of what hap-
pens with urinary MDA in wastewater, preferably using urine from
MDA-only users.
Investigated MDMA excretion products have been shown to
be stable for at least three freeze-thaw cycles in urine as well
for six months at -20 °C.[30] However, conjugate cleaving during
pre-concentration might have occurred in the present study.
The average concentration of HMMA in the samples after 24 h
was 107 ± 27% (α= 0.05, n = 7). The HMMA increase could be
explained by cleaving of the corresponding phase II
metabolites or by biotransformation of MDMA and 3,4-
dihydroxymethamphetamine into HMMA. The increase is how-
ever not significant due to the large variation. The pathway
O-demethylenylation with subsequent O-methylation could
also be a pathway relevant for MDMA, as it shares the
methylenedioxy moiety with MDPV.[4]
HMMA-S showed a high stability and cleaving of the sulfate (and
possibly glucuronide) would be of importance to use HMMA as a
wastewater target for assessing consumption of MDMA. Stability
of HMMA-S corresponds to findings by Gomes et al., who found
conjugated estrogen sulfates to have a high stability for 8 h of incu-
bation in wastewater.[14] In contrast, estrogen glucuronides incu-
bated in wastewater were completely deconjugated after 8 h of
incubation in wastewater at 17 °C; furthermore, the opioid metabo-
lite, morphine-3-glucuronide, has been shown to be unstable in
wastewater after 24 h.[12,13] HMMA conjugate cleavage might be
based on acidic hydrolysis, as previous studies have shown urinary
HMMA concentrations to increasemore than 30-fold after acidic hy-
drolysis of 1mL urine at 160 °C for 20min.[31] As wastewater analysis
requires volumes in the range 50–100mL per sample, acidic hydro-
lysis under elevated temperatures should be worth investigating in
the future.
Conclusions
Screening of pooled urine and urinated soil samples showed COC
and MDMA to be the main consumed illicit drugs in the contribut-
ing festival population. A HILIC-MS/MSmethod was developed and
validated to assess the stability of COC,MDMA, andMDEA excretion
products. Assessing the stability of targets for illicit drug consump-
tion with urinary excretion products should give a better under-
standing on how transformations in the sewer system affects
concentrations of investigated targets. For the first time, HMMA
and HMMA-S were both shown to be stable in wastewater after 8
and 24h of incubation. HMMA should thus be a suitable biomarker
to monitor MDMA consumption in WBE studies. Further studies
should investigate conjugate cleavage of HMMA-S and glucuronide
and the detectability of HMMA in real wastewater samples.
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